NEWS
Fibronostics is proud to announce today that it has secured $6.5 million in funding. In addition – Sven Henrichwark, PhD, has been named the company’s new CEO. June 16, 2022
Fibronostics will be presenting 2 of our clinical studies at the International Liver Congress™ 2022 of the European Association for the Study of the Liver (EASL). Mar 3, 2022
AASLD Poster: Comparing Non-Invasive Tools – LIVERFASt™, FIB-4 and Transient Elastography in Sequential and Combinatory Pathways for NAFLD. Aug 7, 2021 |
AASLD Poster: Long-term prognosis of patients with metabolic dysfunction – associated fatty liver disease by non-invasive methods. Aug 7, 2021
ADA 2021: LIVERFAStTM Has Similar Performance to Liver Biopsy for the Screening of NASH Fibrosis in Type 2 Diabetes Mellitus (T2D). Jun 26, 2021
EASL Poster: Noninvasive LIVERFASt transition rate to liver fibrosis is similar to that estimated with liver biopsy in NAFLD patients. Jun 23, 2021 |
Fibronostics and Fatty Liver Foundation Announce a Patient Education Partnership Dec 07, 2020
Fibronostics US INC, receives CE (Conformité Européenne) mark approval for the product LIVERFASt™ 
AASLD Poster: LIVERFASt is detecting and discriminant different phases of liver disease, with better performances than APRI or FIB-4. Nov 25, 2020 |
|
AASLD Poster: Comparative performance of LIVERFASt™, Fibroscan and other non-invasive test for Severe Fibrosis in NAFLD Patients. Nov 21, 2020 |
LIVERFASt™ provides the right diagnosis of liver disease conditions in type 2 diabetes patients. Nov 01, 2020
Fibronostics on its way to be a Healthcare Technology Powerhouse – Raises $8 Million Series A funding. Aug 24, 2020
Fibronostic’s Chief Scientific Officer,Dr Mona Munteanu, discussed relevance of Non-Invasive Testing for HCC Surveillance in global Webinar series. Aug 21, 2020 |
Know the advantages of non-invasive liver diagnostics over standard biopsy as explained by our CEO, Roni Amiel. Aug 21, 2020
Fibronostics presented a Scientific poster “Assessment of fatty liver disease using a biomarker-based non-invasive algorithm LIVERFASt™ test in South-East Asia”.at the NASH-TAG 2020, UTAH for. Aug 21, 2020
Celebrating a major milestone! Fibronostics granted CPT code for LIVERFASt, our non-invasive liver diagnostics tool. Aug 05, 2020 |
When things go tough due to flight restrictions, we conduct our CMEs through video conferences by our Chief Medical Officer, Dr Ronald Quiambao. Jun 08, 2020
Fibronostics is proud to partner with the CXA Group offering health and wellness screenings with HealthFACTR. Dec 13, 2019
Fibronostics mingles with industry leaders during inspiring few days at the American Association for the Study of Liver Diseases (AASLD) #LiverMtg19. Nov 07, 2019 |
AC Health announces Investment in Fibronostics by launching LIVERFASt and HealthFACTR in its FamilyDOC Clinics. Jul 06, 2019
Fibronostics presented our corporate strategy to current & potential investors in TKS 1 Investor Day in Singapore. Feb 27, 2019 |
